New ultra-sensitive assay for a more complete PK profile
20 Nov 2013
20 November 2013, UK -
LGC's Quotient Bio Analytical Sciences is delighted to launch the Erenna Immunoassay System, the ultra-sensitive assay platform for Pharmacokinetic
-Pharmacodynamic (PK-PD) bioanalytical
In doing so, LGC becomes the first bioanalytical Contract Research Organisation in Europe to offer Singulex Erenna services to support GLP/GCP studies.
The Erenna uses microparticle technology and offers the best PK and PD assay sensitivity available via the use of single molecule counting (SMC). By using this platform LGC is able to offer a range of high-sensitivity assay kits covering a range of therapeutic areas including Inflammation, Oncology and Cardiovascular.
Dr Clare Kingsley, Associate Director for the Biologicals team at LGC, said, “The Singulex Erenna system has enhanced our capability to develop novel, high sensitivity PK and PD assays. In our hands, the increase in sensitivity is between 50-1000 times, compared with other conventional assay platforms - this could prove invaluable in helping our customers with early PK/PD decision making and translate to long term efficiencies in their drug development programmes.”
To find out more, catch up with LGC at the European Bioanalysis Forum
(EBF) Symposium, 20-22 November. Please join us at booth C1.
Singulex will also be attending EBF; visit them at booth B10.